First Tracks Biotherapeutics, Inc. (TRAX) Guidance & Earnings Results
On 2026-08-12 First Tracks Biotherapeutics, Inc. reaffirmed guidance: "Cash runway into Q2…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · read by EquiReason
TRAXFirst Tracks Biotherapeutics, Inc.Follow TRAX — free
—
Price chart with a free account
- Market cap
- 1.6B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 12 Aug 26 | Reaffirmed | Cash runway into Q2 2028 |
First Tracks Biotherapeutics, Inc. — questions
- What guidance did First Tracks Biotherapeutics, Inc. give?
- On 2026-08-12: "Cash runway into Q2 2028"
- When does First Tracks Biotherapeutics, Inc. report earnings?
- First Tracks Biotherapeutics, Inc.'s next earnings report is expected on 2026-11-05.
Every figure on this page comes from First Tracks Biotherapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.